1.0) Histo/cyto proof of SCLC
2.0) Measurable or evaluable disease.
3.0) Extensive dz (outside single RT port).
4.0) Previously untreated, except for RT, for CNS mets or SCV.
5.0) PS 0-2.

Drugs: Topotecan (provided), Taxol, G-CSF, VP-16, CDDP

2.0) Life expectancy of > 12 wks.
3.0) No history of thromboembolic phenomenon such as DVT, PE, or clotted catheter (requiring anticoagulation) within the last year.
Drug: Low-Molecular Weight Heparin (LMWH) (provided)

1.0) Pt. must have histologic or cytologic evidence of breast, lung, colorectal or prostate CA, with evidence of advanced breast CA after having failed first-line chemo; or advanced lung, colorectal, or prostate having failed primary hormonal therapy.

1.0) Hgb in males < 11.5, in females <10.5.
2.0) Currently receiving chemo for advanced cancer.
3.0) PS 0-1
4.0) Life expectancy >/= 6 months.

1.0) Pts. with a history of breast cancer or a concern about taking estrogen for fear of getting breast cancer.
2.0) Bothersome hot flashes (>14 times per week).
3.0) Presence of hot flashes for at least one month prior to study entry.
4.0) Life expectancy >/= 6 months.
5.0) PS 0-1.

1.0) Path (+) breast ca w/clinical evidence of Measurable mets (bone-only dz are eligible)
2.0) 1 prior tx for met dz or failure w/in 6mo's of adjuvent tx- at least one tx with anthracycline or taxane
3.0) RT ok if = 25% of bone marrow

1.0) Recurrent or advanced NSCLC. Recurrent NSCLC must be histo. confirmed if > 1 year since initial diagnosis.
2.0) Pt. must have bidimensionally measurable lesion. (Exception for pts. who achieved a CR from prior therapy.)
3.0) Pt. must have received 4-8 cycles of induction chemo.
4.0) Pt. may not have recieved more than 2 prior regimens.
5.0) Pts. must have completed prior tx within 3-8 wks of enrollment and must begin tx in this study within 8 wks of last dose of prior chemo.
6.0) Pt. may have recieved prior taxol if given on a > 3wk schedule.

1.0) Pt. must have achieved a CR or PR after 1 prior chemo and/or RT Tx.
2.0) Pt. with limited stage SCLC must be randomized 3-12 wks from last dose of chemo, and when relevant > 2wks from RT.
3.0) Pt. with extensive stage SCLC must be randomized 3-6 wks from last dose of chemo.
4.0) Life expectancy >/= 12 weeks.

***SJMH will NOT be participating in this study***

*Credentialing required. Please check your site's credentialing status.*
CURRENT SITES CREDENTIALED:
Genesys, Oakland, St. Alphonsus, St. John

*Check for eligibility to DCP-001*
-Patients must be female.
-Pathologically confirmed diagnosis of breast cancer, clinical stage I-II (T1-3 N0 M0, T0-2 N1 M0).
-Diagnosis must be by needle biopsy; patients diagnosed by surgical excision are excluded
-Patients must have ER and PR negative breast cancer
-No patients with previous ipsilateral invasive breast cancer or DCIS
-No patients with bilateral breast cancer
-No patients with known deleterious mutations in breast cancer (BRCA) genes
-No current history of receiving hormonal therapy, tamoxifen, and or aromatase inhibitors for therapeutic measures
-No history of chemotherapy for cancer within 6 months prior to registration
-No patients scheduled to receive partial breast irradiation following breast conserving surgery
-Patients must be eligible for breast conserving therapy
-Patients must be suitable to undergo MRI
-No prior MRI of study breast within the 12 months prior to registration
-No history of breast biopsy (including FNA) of the study breast within 6 months prior to the MRI

-Neoadjuvant chemotherapy patients are allowed

-Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy
-Clinical T2-T4c, any N, M0 invasive breast cancer with the goal being surgery to complete excision of the tumor in the breast and the lymph node.
-The extent of disease is a solitary lesion where the lesion is palpable, can be measured bidimensionally, and largest diameter is at least 2cm.
-Patients with contralateral ductal carcinoma in situ and/or invasive breast cancer are NOT eligible.

-Patients with multi-focal breast cancer (defined as more than one lesion of invasive breast cancer in the same breast separated from the dominant breast lesion by less than 5 cm of radiologically normal breast tissue) are eligible.

-Disease must be ER positive
-Disease must be HER2 negative
-ECOG PS 0-2
-Patients must be postmenopausal
-No prior treatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entry.